Revenue grew 2.26% to ¥6.17 billion, but net profit fell 29.59% to ¥1.09 billion due to price declines and higher impairment. Gross margin dropped to 43.75%. The company remains a domestic leader, investing heavily in R&D and production expansion, while facing policy and margin pressures.
Original document: Beijing Tiantan Biological Products Corporation Limited Class A [600161] Annual Report — Mar. 28 2026
Select market data provided by ICE Data Services. Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc.Copyright © 2026, American Bankers Association. CUSIP Database provided by FactSet Research Systems Inc. All rights reserved. SEC fillings and other documents provided by Quartr.© 2026 TradingView, Inc.
Beijing Tiantan Biological Products: Net profit dropped 29.59% on flat revenue as margins and cash flow declined amid policy headwinds – TradingView
Leave a Comment
